Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
26.44
-0.71 (-2.63%)
Sep 10, 2026, 4:00 PM EDT - Market closed
Zymeworks Revenue
Zymeworks had revenue of $3.23M in the quarter ending June 30, 2026, a decrease of -90.98%. This brings the company's revenue in the last twelve months to $35.77M, down -67.47% year-over-year. In the year 2025, Zymeworks had annual revenue of $105.97M with 38.87% growth.
Revenue (ttm)
$35.77M
Revenue Growth
-67.47%
P/S Ratio
50.52
Revenue / Employee
$160,723
Employees
231
Market Cap
1.88B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 105.97M | 29.66M | 38.87% |
| Dec 31, 2024 | 76.30M | 292.00K | 0.38% |
| Dec 31, 2023 | 76.01M | -336.47M | -81.57% |
| Dec 31, 2022 | 412.48M | 385.80M | 1,446.03% |
| Dec 31, 2021 | 26.68M | -12.27M | -31.50% |
| Dec 31, 2020 | 38.95M | 9.41M | 31.84% |
| Dec 31, 2019 | 29.54M | -23.48M | -44.28% |
| Dec 31, 2018 | 53.02M | 1.26M | 2.43% |
| Dec 31, 2017 | 51.76M | 40.75M | 370.18% |
| Dec 31, 2016 | 11.01M | 1.35M | 13.96% |
| Dec 31, 2015 | 9.66M | 7.99M | 478.44% |
| Dec 31, 2014 | 1.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vericel | 306.30M |
| Vir Biotechnology | 303.23M |
| Maravai LifeSciences Holdings | 208.78M |
| Xencor | 104.97M |
| Nanobiotix | 38.27M |
| Stoke Therapeutics | 27.59M |
| Generate Biomedicines | 26.48M |
ZYME News
- 2 days ago - Zymeworks Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 7 days ago - Zymeworks price target raised to $33 from $31 at JPMorgan - TheFly
- 15 days ago - Zymeworks price target raised to $38 from $37 at Citi - TheFly
- 15 days ago - Zymeworks price target raised to $55 from $51 at H.C. Wainwright - TheFly
- 16 days ago - Zymeworks says partner Jazz receives FDA approval for Ziihera regimens - TheFly
- 4 weeks ago - Zymeworks price target raised to $44 from $40 at B. Riley - TheFly
- 4 weeks ago - Citi adds ‘upside 90-day catalyst watch’ on Zymeworks in FDA decision - TheFly
- 4 weeks ago - Zymeworks price target raised to $32 from $31 at Truist - TheFly